Olivier Boss

Dr. Boss is an expert in energy metabolism and mitochondria, and has broad experience in various industry roles, most recently in key R&D positions at Sirtris (acquired by GlaxoSmithKline) and Adipogenix. Previously, he served as head of a target discovery/validation group for diabetes and obesity, and led a major program on mitochondrial bioenergetics at Novartis. Prior to this Dr. Boss discovered Energesis' brown adipocyte progenitor cells in skeletal muscle as well as the novel thermogenic mitochondrial uncoupling proteins UCP2 and UCP3. He has more than 50 publications in peer-reviewed journals, and his report on the discovery of UCP2 and 3 has become one of the most frequently cited papers in physiology. He also edited a book on the Pharmacotherapy of Obesity (CRC Press) and has several issued and pending patents. Dr. Boss performed his post-doctoral training at Harvard Medical School with Dr. Brad Lowell and working in close association with the laboratory of Bruce Spiegelman.